topic is largely or exclusively about orthopedic products, technologies, markets and/or companies
Cancer is a significant opportunity for the development of tissue engineering and cell therapies, but it is more than just an opportunity currently, since many companies are active and the market for cancer cell/tissue therapies already stands at nearly $500 million.
Currently, OSI Pharmaceuticals has a commanding lead in this area, with its Tarceva being [...]
With the initial markets for cell therapy and tissue engineering being best represented by clinical applications in orthopedics and skin/integumentary, a sampling of technologies at various states of development within each is worth considering for insights into likely near-term market impact.
Below are select technologies under development by companies in cell therapy and tissue engineering. While [...]
The use of autologous, allogeneic and xenogeneic cells and tissues, the use of biomaterials, cell scaffolding and other approaches to tissue repair and regeneration has become part of arsenal of a number of clinical specialties, with high caseload and market revenue in these areas. In particular, orthopedics and skin applications are well established. And, while [...]
Our research into the products, technologies, companies and markets for tissue engineering and cell therapy has revealed that the 2009 market was at $6.9 billion. The market has grown dramatically, in commercialized products and company activity, over the past few years and is on an accelerated growth rate as technology hurdles are overcome and clinical [...]
The number of companies with approved products and measurable revenues in the field of cell therapy and tissue engineering has exceeded the expectation of many (though not all) in the industry.
Markets such as cell/tissue are often characterized by overestimated evaluations of commercial potential and underestimated consideration of the actual challenges. Indeed many technology challenges remain [...]
Tissue engineering involves taking either autologous, allogeneic or xenogeneic cells and redirecting those cells to carry out fundamental processes. Often the researcher will use a biomaterial matrix and seed the cells into this matrix. The redirection may take the form of stimulating the cells to become stem cells or precursor cells, or it may mean [...]
The areas of greatest opportunity in medtech are those which have already demonstrated they have plenty of upside, even if a robust number of competitors have already begun targeting them.
Areas of the strongest market growth in medical technologies that we are seeing have emerged out of the major segments we have tracked in recent analyses. [...]
The global market for medical devices is $200 billion opportunity and at least 13% of this market involves products that provide the controlled application of energy to tissue. The segment is dominated by high technology products ranging from devices that can heat and cool tissue over a 600° C temperature range of -200° C to [...]
The use of energy-based systems for the routine management of disease and trauma in the orthopedic arena encompasses multiple energy types. The manufacturers PhotoThera, ArthroCare, Bioelectron, Biowave, ConMed, Medical Technologies, Siemens, Smith & Nephew (Oratec), J&J (Mitek), ConMed and Stryker market a variety of energy-based systems for these purposes.
These systems offer the following features and [...]
In cardiovascular and spine surgery, multi-billion dollar markets were created from entirely new procedures between 1980 and 2000, with subsequent segmentation in later years particularly as new minimally invasive procedures were developed towards the end of the 20th century. In the cardiovascular arena, the development of new procedures for angioplasty and bypasses in the late [...]
Contact:
